Drugs are extensively used in medicine when they are unlikely to produce a benefit to the patient. In most instances this does no apparent harm to the patient but sometimes (for example, the extensive use of thorotrast) the results are tragic. Even when the patient is not injured, overuse of medicines is an undesirable and money-wasting behavioral pattern. Several factors relating to the social process of drug use which encourage overprescribing are discussed and the Principles of Irrational Drug Therapy are derived. These principles are presented as negative role models for the use of medicines in developing countries.
Get full access to this article
View all access options for this article.
References
1.
SimmonsH. E.StolleyP. D.This is medical progress?J.A.M.A.227: 1023–1028, 1974.
2.
FinlandM.Emergence of antibiotic resistance in hospitals. Rev. Infect. Dis.1: 4–21, 1979.
3.
MillerR. R.Propoxyphene: A review. Amer. J. Hosp. Pharm.34: 414–423, 1977.
4.
Anon. Top 200 drugs. Pharmacy Times (April): 35–41, 1974.
5.
Anon. Fatalities due to propoxyphene. F.D.A. Bulletin9(1): 2, 1979.
6.
WolfeS. M.ColeyC. M.Pitts That Don't Work. Farrar, Strauss, and Giroux Publishers, New York, 1981.
7.
KripkeD.Why we need a tax on sleeping pills. South. Med. J.76: 632–636, 1983.
8.
MoermanD. E.Placebo effect in the treatment of ulcer disease. Med. Anthropol. Quart.14(4): 19, 1983.
9.
BrintonL. A.Menopausal estrogen use and risk of breast cancer. Cancer47: 2517–2522, 1981.
10.
BrockellbankV. C.Drug prescribing during pregnancy: A controlled study of Tennessee Medicaid recipients. Amer. J. Obstet. Gynecol.132: 235–244, 1978.
11.
ClarkL. C.PortierK. M.Diethylstilbesterol and the risk of cancer. New Eng. J. Med.300: 262–263, 1979.
12.
BeralV.ColwellL.Randomised trial of high doses of stilbesterol and ethisterone in pregnancy: Long-term follow up of mothers. Brit. J. Med.281: 1098–1101, 1980.
13.
BrackbillY.BerendesH. W.Dangers of diethylstilbesterol: Review of a 1953 paper. Lancet2: 520, 1978.
14.
KarchF. E.Adverse drug reactions: A matter of opinion. Clin. Pharmac. Ther.19: 489–492, 1976.
15.
LasagnaL.The halcion story: Trial by media. Lancet1: 815–816, 1980.
16.
CromptonD. O.Medical ethics and hospital acquired disease. Lancet2: 146, 1978.
TaussigH. B.The evils of camouflage as illustrated by thalidomide. New Eng. J. Med.269: 92–94, 1972.
38.
WilliamsB. A.F.D.A. made ‘wrong decision’ on sale of vitamin E drug. St. Petersburg Times. May 5, 1984 (Associated Press).
39.
RickelsK.Are benzodiazepines overused and abused?Br. J. Clin. Pharmac.11: 815–835, 1983.
40.
MorganJ. P.The politics of medication. In Controversies in Therapeutics, edited by LasagnaL., W. B. Saunders, Philadelphia, 1980.
41.
NorrisR.Pills, Pesticides and Profits: The International Trade in Toxic Substances. North River Press, New York, 1982.
42.
YudkinJ. S.The economics of pharmaceutical supply in Tanzania. Int. J. Health Serv. 10: 455–471, 1980.
43.
LedogarR. J.Hungry for Profits: U.S. Food and Drug Multinationals in Latin America. IDOC/North America, New York, 1975.
44.
GlucksbergJ.SingerJ.The multinational drug companies and Zaire: Their adverse effect on cost and availability of essential drugs. Int. J. Health Serv. 12: 381–387, 1982.
45.
LernouxP.Cry of the People. Doubleday and Company, Garden City, New York, 1980.
